PRURIGO NODULARIS | SANOFI GENZYME EFC16460 | PHASE III

Status: RECRUITING

Drug: SAR231893 / REGN668

Timeline: TBD

Detailed Description

This is a randomized, double-blind, placebo-controlled, multi-centre, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable.

Inclusion

• Informed consent
• Male or female
• 18 to 80 years of age
• Diagnosed by a dermatologist with prurigo nodularis (PN) for at least 3 months

Exclusions

• Female subjects who are pregnant or lactating
• Presence of skin morbidities other than PN and mild atopic dermatitis that may interfere with the assessment of the study outcomes
• Uncontrolled thyroid disease

If you’re interested in participating, please SEND US AN EMAIL AND/OR CONTACT US and our research team will be in touch.